By characterizing metabolic and immune microenvironment reveal potential prognostic markers in the development of colorectal cancer
Colon adenocarcinoma (COAD) is one of the deadliest cancers in the world and survival rates vary significantly between early and advanced stage patients. Therefore, the identification of the pathogenesis in the development of COAD and prognostic markers is urgently demanded. Herein, we collected RNA...
Gespeichert in:
Veröffentlicht in: | Frontiers in bioengineering and biotechnology 2022-08, Vol.10, p.822835-822835 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Colon adenocarcinoma (COAD) is one of the deadliest cancers in the world and survival rates vary significantly between early and advanced stage patients. Therefore, the identification of the pathogenesis in the development of COAD and prognostic markers is urgently demanded. Herein, we collected RNA-seq and somatic mutation data of COAD for statistical analysis. Clinical stage-specific differentially expressed genes (DEGs) and tumor development-dependent DEGs were identified. By characterizing the metabolic and immune features of COAD between stages, we found that the energy supply and inflammatory response of advanced tumors were suppressed. Next, the
ETS1, AR, GATA1, GATA2, SREBF1, FOXP3, STAT4,
and
NFKB1
were identified to drive the metabolic and immune-related pathways in the development of COAD. The three potential prognostic markers (
HOXC8, IRF7,
and
CXCL13
) were identified based on Cox regression analysis. Additionally, immune infiltration analysis revealed that the resting CD4
+
T cell was significantly related to the overall survival (OS) of COAD patients. Collectively, the specific metabolic and immune characteristics of advanced patients and the identified prognostic biomarkers will contribute to the development of precision medicine. |
---|---|
ISSN: | 2296-4185 2296-4185 |
DOI: | 10.3389/fbioe.2022.822835 |